Genmab (HuMax-IL8) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Genmab (HuMax-IL8) General Information
Description
An antibody license for treatment of selected cancers. The asset is a high-affinity, fully human antibody directed towards IL-8. IL-8 has been shown to be involved in several aspects of tumor development, including tumor spread (metastasis), cancer stem cell renewal and tumor immunosuppression.
Contact Information
Corporate Office
- Copenhagen
- Denmark
Corporate Office
- Copenhagen
- Denmark
Genmab (HuMax-IL8) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genmab (HuMax-IL8) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Genmab (HuMax-IL8) FAQs
-
Where is Genmab (HuMax-IL8) headquartered?
Genmab (HuMax-IL8) is headquartered in Copenhagen, Denmark.
-
What industry is Genmab (HuMax-IL8) in?
Genmab (HuMax-IL8)’s primary industry is Buildings and Property.
-
Is Genmab (HuMax-IL8) a private or public company?
Genmab (HuMax-IL8) is a Private company.
-
What is Genmab (HuMax-IL8)’s current revenue?
The current revenue for Genmab (HuMax-IL8) is .
-
Who are Genmab (HuMax-IL8)’s investors?
Genmab has invested in Genmab (HuMax-IL8).
-
When was Genmab (HuMax-IL8) acquired?
Genmab (HuMax-IL8) was acquired on 30-May-2012.
-
Who acquired Genmab (HuMax-IL8)?
Genmab (HuMax-IL8) was acquired by Cormorant Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process